Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-blind, placebo controlled randomized study of co-administering testosterone with PDE5 [phosphodiesterase V] inhibitors in patients non-responders to PDE5 inhibitors alone

Next Previous
Trial Profile

Double-blind, placebo controlled randomized study of co-administering testosterone with PDE5 [phosphodiesterase V] inhibitors in patients non-responders to PDE5 inhibitors alone

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Testosterone (Primary) ; Tadalafil
  • Indications Erectile dysfunction
  • Focus Therapeutic Use
  • Acronyms TADTEST

Most Recent Events

  • 27 Dec 2012 New source identified and integrated (German Clinical Trials Register; DRKS00004081).
  • 08 May 2009 Results presented at the 104th Annual Meeting of the American Urological Association (AUA), 2009.
  • 24 Aug 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top